Wilkinson Thomas J, Yates Thomas, Baker Luke A, Zaccardi Francesco, Smith Alice C
Leicester Kidney Lifestyle Team, Department of Health Sciences University of Leicester Leicester UK.
Leicester NIHR Biomedical Research Centre Leicester UK.
JCSM Rapid Commun. 2022 Jan-Jun;5(1):3-9. doi: 10.1002/rco2.47. Epub 2021 Jul 3.
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2. The role of skeletal muscle mass in modulating immune response is well documented. Whilst obesity is well established as a key factor in COVID-19 and outcome, no study has examined the influence of both sarcopenia (low muscle mass) and obesity, termed 'sarcopenic obesity' on the risk of severe COVID-19.
This study uses data from UK Biobank. Probable sarcopenia was defined as low handgrip strength. Sarcopenic obesity was mutually exclusively defined as the presence of obesity and low muscle mass [based on two established criteria: appendicular lean mass (ALM) adjusted for either (i) height or (ii) body mass index]. Severe COVID-19 was defined by a positive severe acute respiratory syndrome coronavirus 2 test result in a hospital setting and/or death with a primary cause reported as COVID-19. Fully adjusted logistic regression models were used to analyse the associations between sarcopenic status and severe COVID-19. This work was conducted under UK Biobank Application Number 52553.
We analysed data from 490 301 UK Biobank participants (median age 70.0 years, 46% male); 2203 (0.4%) had severe COVID-19. Individuals with probable sarcopenia were 64% more likely to have had severe COVID-19 (odds ratio 1.638; < 0.001). Obesity increased the likelihood of severe COVID-19 by 76% ( < 0.001). Using either ALM index or ALM/body mass index to define low muscle mass, those with sarcopenic obesity were 2.6 times more likely to have severe COVID-19 (odds ratio 2.619; < 0.001). Sarcopenia alone did not increase the risk of COVID-19.
Sarcopenic obesity may increase the risk of severe COVID-19, over that of obesity alone. The mechanisms for this are complex but could be a result of a reduction in respiratory functioning, immune response, and ability to respond to metabolic stress.
2019冠状病毒病(COVID-19)是由严重急性呼吸综合征冠状病毒2引起的一种传染病。骨骼肌质量在调节免疫反应中的作用已有充分记录。虽然肥胖已被确认为COVID-19及其预后的一个关键因素,但尚无研究探讨肌肉减少症(低肌肉质量)和肥胖(即“肌少症肥胖”)对重症COVID-19风险的综合影响。
本研究使用了英国生物银行的数据。可能的肌肉减少症定义为握力低。肌少症肥胖被相互排斥地定义为存在肥胖和低肌肉质量[基于两个既定标准:(i)根据身高或(ii)体重指数调整的四肢瘦体重(ALM)]。重症COVID-19定义为在医院环境中严重急性呼吸综合征冠状病毒2检测结果呈阳性和/或主要死因报告为COVID-19的死亡。使用完全调整的逻辑回归模型分析肌少症状态与重症COVID-19之间的关联。本研究是在英国生物银行申请号52553下进行的。
我们分析了来自490301名英国生物银行参与者的数据(中位年龄70.0岁,46%为男性);2203人(0.4%)患有重症COVID-19。可能患有肌肉减少症的个体患重症COVID-19的可能性高出64%(比值比1.638;<0.001)。肥胖使重症COVID-19的可能性增加了76%(<0.001)。使用ALM指数或ALM/体重指数来定义低肌肉质量,患有肌少症肥胖的个体患重症COVID-19 的可能性高出2.6倍(比值比2.619;<0.001)。单纯的肌肉减少症不会增加COVID-19的风险。
肌少症肥胖可能比单纯肥胖更易增加重症COVID-19的风险。其机制复杂,但可能是呼吸功能、免疫反应和应对代谢应激能力下降的结果。